<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77802</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Delection syndrome In Xp21: An unusual form of presentation</dc:title>
<dc:creator>Cánovas Martínez, A</dc:creator>
<dc:creator>Hernández Marco, R</dc:creator>
<dc:creator>Martínez Castellano, F</dc:creator>
<dc:creator>Millán Salvador, J. M</dc:creator>
<dc:creator>Sanz Ruiz, I</dc:creator>
<dc:creator>Bretón Martínez, J. R</dc:creator>
<dc:creator>Del Castillo Villaescusa, C</dc:creator>
<dc:creator>Codoñer Franch, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introduction. We report a case of an infant where the association of Duchenne&#146;s muscular dystrophy (DMD) andpseudohypertriglyceridaemia led to the diagnosis of contiguous gene deletion syndrome in Xp21. Case report. A 7-month-oldmale infant who was referred due to psychomotor retardation. The examination revealed pronounced axial hypotonia. Labfindings showed high levels of muscular enzymes with creatine phosphokinase levels of 12,829 IU/L, together with high bloodlevels of triglycerides. Electromyogram findings were consistent with myopathic compromise. The genetic study for dystrophinopathiesrevealed the existence of a deletion in the dystrophin gene. Further lab findings identified high glycerol concentrationsboth in blood and in urine that were compatible with a glycerol kinase deficiency. The genetic study confirmed the existence ofa deletion in Xp21 of the genes responsible for DMD, the glycerol kinase deficiency, the congenital adrenal hypoplasia (geneDAX1) and mental retardation (gene IL1RAPL1). Conclusions. In infants and small children with myopathic compromise,increased levels of creatine phosphokinase and pseudohypertriglyceridaemia it is essential to take into account contiguousgene deletion syndrome in Xp21 to be able to prevent and treat the metabolic complications arising from adrenal hypoplasia (AU)</dc:description>
<dc:source>Rev Neurol;49(9): 472-474, nov. 2009. ilus</dc:source>
<dc:identifier>ibc-77802</dc:identifier>
<dc:title xml:lang="es">Síndrome de deleción de genes contiguos en Xp21: una forma inusual de presentación</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d7399</dc:subject>
<dc:subject>^d34190^s22053</dc:subject>
<dc:subject>^d50495^s22012</dc:subject>
<dc:subject>^d34190^s22012</dc:subject>
<dc:subject>^d34190^s22016</dc:subject>
<dc:subject>^d15358^s22053</dc:subject>
<dc:subject>^d15358^s22031</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d24691^s22031</dc:subject>
<dc:subject>^d24691^s22033</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d30934^s22033</dc:subject>
<dc:subject>^d30934^s22012</dc:subject>
<dc:subject>^d50495^s22027</dc:subject>
<dc:type>article</dc:type>
<dc:date>200911</dc:date>
</metadata>
</record>
</ibecs-document>
